Topical Multi-Agent Compositions for Keloid Recurrence Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for keloids are inadequate, with high recurrence rates and limited effective methods that do not require specialized equipment or systemic side effects, particularly for dark-skinned individuals, where genetic and epigenetic factors contribute significantly to the disease.
Innovation Solution
Pharmaceutical compositions comprising therapeutic agents such as SERPINE1 inhibitors, histone acetyltransferase inhibitors, insulin-like growth factor inhibitors, and anti-hypertensive agents, which can be administered topically or systemically to target multiple pathways involved in keloid formation, potentially combined with radiation or surgical resection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If surgical resection alone is used to treat keloids, then the treatment is simple and does not require specialized equipment, but the recurrence rate is very high
Solution Approach 1:
The patent combines surgical resection with topical application of pharmaceutical compositions containing multiple therapeutic agents (SERPINE1 inhibitors, HAT inhibitors, HDAC inhibitors, IGF inhibitors, anti-hypertensive agents). This combination approach maintains the simplicity of surgical procedure while adding a topical treatment that prevents recurrence through synergistic inhibition of fibroblast proliferation and collagen deposition.
Solution Approach 2:
The pharmaceutical composition is a composite formulation containing multiple therapeutic agents with different mechanisms of action. These agents work synergistically to target multiple pathways involved in keloid formation (serine protease inhibition, histone modification, growth factor inhibition, calcium channel blocking), thereby preventing recurrence while maintaining treatment simplicity.
2Ease of operation
If intralesional steroids are used to treat keloids, then the treatment is simple to administer, but the response is highly variable and systemic side effects occur
Solution Approach 1:
The patent uses a composite pharmaceutical composition containing multiple therapeutic agents (SERPINE1 inhibitors, HAT inhibitors, HDAC inhibitors, IGF inhibitors, anti-hypertensive agents) instead of single-agent steroid therapy. This multi-component formulation provides consistent and reliable treatment response by targeting multiple pathways simultaneously, while topical application minimizes systemic side effects.
Solution Approach 2:
The patent changes the administration route from intralesional injection to topical application, and changes the therapeutic agent profile from single-agent steroids to multi-agent compositions. These parameter changes improve treatment consistency and reduce variability in patient response while maintaining ease of administration.
3Reliability
If superficial radiation therapy is used to prevent keloid recurrence, then the effectiveness is high, but specialized equipment is required and patients experience reluctance due to cancer therapy association
Solution Approach 1:
The patent replaces the mechanical/radiological system (superficial radiation therapy requiring specialized equipment) with a chemical/pharmaceutical system (topical application of multi-agent compositions). This substitution maintains high effectiveness in preventing recurrence while eliminating the need for specialized equipment and reducing patient reluctance associated with cancer therapy.
Solution Approach 2:
The patent changes the therapeutic modality from radiation therapy to topical pharmaceutical application. This parameter change maintains the effectiveness in preventing keloid recurrence while eliminating device complexity and patient psychological barriers associated with radiation and cancer therapy.
4Reliability
If high doses of single therapeutic agents are used to treat keloids, then the treatment effectiveness may be sufficient, but systemic side effects increase
Solution Approach 1:
The patent uses a composite pharmaceutical composition containing multiple therapeutic agents (SERPINE1 inhibitors, HAT inhibitors, HDAC inhibitors, IGF inhibitors, anti-hypertensive agents) that work synergistically. This allows the use of lower doses of each individual agent while maintaining or improving overall treatment effectiveness and reducing systemic side effects through distributed dosing across multiple mechanisms of action.
Solution Approach 2:
The patent employs multiple agents at lower doses rather than a single agent at high dose. Each agent contributes partially to the overall therapeutic effect, and their combined action achieves sufficient treatment effectiveness while minimizing the harmful effects associated with high-dose single-agent therapy.
Data Source
AI summary
This disclosure relates to pharmaceutical compositions comprising one or more therapeutic agents selected from a SERPINE1 serine protease inhibitor, a histone acetyltransferase inhibitor, a histone deacetylase inhibitor, an insulin-like growth factor inhibitor, an anti-hypertensive agent, a topoisomerase II inhibitor, a tyrosine kinase inhibitor, an agent that downregulates growth factors or any combination thereof, and methods of treating fibrotic disorders, including keloid, pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, renal fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, and/or scleroderma using the same. The disclosed methods can be accompanied by application of radiation and/or surgical resection. For treating keloids, the compositions can be formulated topically and do not cause systemic side effects. For treating fibrotic diseases of internal organs, the compositions can be administered systemically or delivered to the affected organs. The compositions can include two or more therapeutic agents that work synergistically, allowing lower doses of each therapeutic agent.